• 出版社/出版日：Mordor Intelligence / 2020年8月
|Single User||￥480,250 (USD4,250)||▷ お問い合わせ|
|Team User||￥536,750 (USD4,750)||▷ お問い合わせ|
|Corporate License||￥678,000 (USD6,000)||▷ お問い合わせ|
Anthrax is one of the most common livestock diseases in the world. According to a report published by WHO (World Health Organization), although national programs have resulted in the containment of anthrax globally, it is still prevalent, primarily due to the lack of experience of the most recent generations of veterinarians in identifying and reporting the disease, and the discontinuation of vaccination against the disease.
Livestock diseases are contributing to a set of problems within livestock production systems. These problems include productivity losses, uncertain food security, and loss of income, among others, which are adversely affecting human health. Livestock disease management can reduce disease through the vaccination of animals. Footandmouth disease (FMD) is highly contagious among clovenhoofed animals, like cattle, swine, sheep, and goats, as well as many species of wild animals. Thus, increasing incidences of livestock diseases are the major factors driving the growth of the veterinary vaccines market, as these diseases can be eradicated with the periodic use of vaccines for animals.
Other factors, which are driving the veterinary vaccines market growth, are rising incidence of zoonotic diseases and initiatives taken by government agencies, animal associations, and leading players.
[Key Market Trends]
Companion Animal Vaccines Segment is Expected to Show Better Growth in the Forecast Period
Veterinary vaccines are used primarily for livestock, as they suffer from various diseases, such as bluetongue virus, footandmouth disease (FMD), and rabies. However, the companion vaccine is expected to witness high growth, over the forecast period. Vaccination has long been a principal point of canine practice, as it is one of the safest and most costeffective means of infectious disease prevention.
The rapid proliferation of companion animal vaccines, advancement in diagnostic services and vaccine technology, and concerns over vaccine safety have contributed to the strong growth of the segment. Moreover, the market is being positively affected by evolving vaccine protocols with continuously changing patterns of diseases and the pet population.
[North America Dominates the Veterinary Vaccines Market]
North America holds the largest market share. Veterinary vaccines in the United States are regulated by the Center for Veterinary Biologics (CVB) in the Animal and Plant Health Inspection Service (APHIS). The CVB grants establishment and product license to animal health companies, in order to manufacture and sell veterinary biologics.
Vaccination, in companion and wildlife animals for zoonotic diseases, had a great impact on reducing the incidence of zoonotic diseases. Furthermore, the rising awareness about the prevention of diseases and technological advancements are expected to propel the demand for veterinary vaccine in the region.
The veterinary vaccines market is fairly competitive and consists of several major players. Most of these major players enjoy a global presence, and they are facing intense competition in emerging economies. The emerging countries are becoming hotspots for significant competition, due to a rapidly expanding market size, fueled by rising concerns over food safety and the increasing adoption of companion animals.
[Reasons to Purchase this report]
The market estimate (ME) sheet in Excel format
3 months of analyst support
Please note: This publisher does offer titles that are created upon receipt of order. If you are purchasing a PDF Email Delivery option above, the report will take approximately 2 business days to prepare and deliver.レポート目次
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Incidence of Livestock Diseases
4.2.2 Increasing Incidence of Zoonotic Diseases
4.2.3 Initiatives by Government Agencies, Animal Associations, and Leading Players
4.3 Market Restraints
4.3.1 High Storage Costs for Vaccines
4.3.2 Shortage of Veterinarians and Skilled Farm Workers
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Vaccine Type
5.1.1 Livestock Vaccines
18.104.22.168 Bovine Vaccines
22.214.171.124 Poultry Vaccines
126.96.36.199 Porcine Vaccines
188.8.131.52 Other Livestock Vaccines
5.1.2 Companion Animal Vaccines
184.108.40.206 Canine Vaccines
220.127.116.11 Feline Vaccines
18.104.22.168 Equine Vaccines
5.2 By Technology
5.2.1 Live Attenuated Vaccines
5.2.2 Inactivated Vaccines
5.2.3 Toxoid Vaccines
5.2.4 Recombinant Vaccines
5.2.5 Other Technologies
5.3 By Geography
5.3.1 North America
22.214.171.124 United States
126.96.36.199 United Kingdom
188.8.131.52 Rest of Europe
184.108.40.206 South Korea
220.127.116.11 Rest of Asia-Pacific
5.3.4 Middle-East and Africa
18.104.22.168 South Africa
22.214.171.124 Rest of Middle-East and Africa
5.3.5 South America
126.96.36.199 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Zoetis Inc.
6.1.2 Merck & Co. Inc.
6.1.4 Hester Biosciences Limited
6.1.5 Elanco Animal Health
6.1.6 Boehringer Ingelheim International GmbH
6.1.7 Ceva Sante Animale
6.1.8 Phibro Animal Health Corporation
7 MARKET OPPORTUNITIES AND FUTURE TRENDS